CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation

Vaccine

Volumn 21, Issue 19-20, 2003, Pages 2268-2272

  Brandão, Joana G ^a   Scheper, Rik J ^a   Lougheed, Sinéad M ^a   Curiel, David T ^a,b   Tillman, Bryan W ^b   Gerritsen, Winald R ^a   Van Den Eertwegh, Alfons J M ^a   Pinedo, Herbert M ^a   Haisma, Hidde J ^c   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adenoviral; Dendritic cells; Transduction

Indexed keywords

BISPECIFIC ANTIBODY; CD40 ANTIGEN; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADENOVIRUS; ANTIGEN SPECIFICITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; GENE TRANSFER; GENETIC TRANSDUCTION; IMMUNOTHERAPY; IN VIVO STUDY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 12444345503     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00050-1     Document Type: Article

References (28)

1. Biragyn A., Kwak L.W. Designer cancer vaccines are still in fashion. Nat. Med. 6(9):2000;966-968.
2. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109(12):2002;1519-1526.
3. Foged C., Sundblad A., Hovgaard L. Targeting vaccines to dendritic cells. Pharm. Res. 19(3):2002;229-238.
4. Jonuleit H., Schmitt E., Steinbrink K., Enk A.H. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22(7):2001;394-400.
5. Hawiger D., Inaba K., Dorsett Y.et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194(6):2001;769-779.
6. Geissmann F., Dieu-Nosjean M.C., Dezutter C.et al. Accumulation of immature langerhans cells in human lymph nodes draining chronically inflamed skin. J. Exp. Med. 196(4):2002;417-430.
7. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393(6684):1998;480-483.
8. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 393(6684):1998;478-480.
9. Mackey M.F., Gunn J.R., Maliszewsky C., Kikutani H., Noelle R.J., Barth R.J. Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 161(5):1998;2094-2098.
10. Jenne L., Schuler G., Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22(2):2001;102-107.
11. Kirk C.J., Mule J.J. Gene-modified dendritic cells for use in tumor vaccines. Hum. Gene Ther. 11(6):2000;797-806.
12. Arthur J.F., Butterfield L.H., Roth M.D.et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4(1):1997;17-25.
13. Zhong L., Granelli-Piperno A., Choi Y., Steinman R.M. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29(3):1999;964-972.
14. Dietz A.B., Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood. 91(2):1998;392-398.
15. Rea D., Havenga M.J., van Den A.M.et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene- encoded antigen presentation to cytotoxic T cells. J. Immunol. 166(8):2001;5236-5244.
16. Tillman B.W., de Gruijl T.D., Luykx-de Bakker S.A.et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162(11):1999;6378-6383.
17. Rea D., Schagen F.H., Hoeben R.C.et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J. Virol. 73(12):1999;10245-10253.
18. de Gruijl TD, Luykx-de Bakker SA, Tillman Bw, et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol 2002;169(9):5322-31.
19. Tillman B.W., Hayes T.L., DeGruijl T.D., Douglas J.T., Curiel D.T. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60(19):2000;5456-5463.
20. Pereboev A.V., Asiedu C.K., Kawakami Y.et al. Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 9(17):2002;1189-1193.
21. Francisco J.A., Gilliland L.K., Stebbins M.R., Norris N.A., Ledbetter J.A., Siegall C.B. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res. 55(14):1995;3099-3104.
22. Francisco J.A., Gawlak S.L., Siegall C.B. Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin. J. Biol. Chem. 272(39):1997;24165-24169.
23. Watkins S.J., Mesyanzhinov V.V., Kurochkina L.P., Hawkins R.E. The adenobody approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4(10):1997;1004-1012.
24. Haisma H.J., Grill J., Curiel D.T.et al. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther. 7(6):2000;901-904.
25. Kontermann R.E., Martineau P., Cummings C.E.et al. Enzyme immunoassays using bispecific diabodies. Immunotechnology. 3(2):1997;137-144.
26. Nettelbeck D.M., Miller D.W., Jerome V.et al. Targeting of adenovirus to endothelial cells by a bispecific single - chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol. Ther. 3(6):2001;882-891.
27. Bontkes H.J., de Gruijl T.D., Schuurhuis G.J., Scheper R.J., Meijer C.J., Hooijberg E. Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood growth factor combination determines proliferation rate and functional outcome. J. Leukoc. Biol. 72(2):2002;321-329.
28. Jonuleit H., Tuting T., Steitz J. Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther. 7(3):2000;249-254.